PDCD1 and hepatocellular carcinoma: Another study suggested that postoperative anti-PD-1 antibody treatment in high-risk recurrent HCC patients demonstrated better postoperative 1-year, 2-year, 3-year, and 4-year OS rates (93.1% vs. 85.3%, 86.8% vs. 70.2%, 78.2% vs. 47.7%, 51.1% vs. 30.0%) and postoperative 1-year, 2-year, 3-year RFS rates (81.7% vs. 68.4%, 77.0% vs. 47.7%, 52.3% vs. 25.8%) compared to the non-anti-PD-1 antibody group (40).